title: Rituximab treatment for adult purpura nephritis with nephrotic syndrome.
abstract: The case of a 68-year-old woman with purpura nephritis associated with nephrotic syndrome is herein described. The patient's clinical course and the findings of a renal biopsy study revealed purpura nephritis. Following treatment with corticosteroids and intravenous cyclophosphamide accompanied by an angiotensin II type I receptor-blocker, an anti-platelet drug and an hydroxymethylglutaryl (HMG)-CoA, the proteinuria mildly decreased. Additional rituximab therapy led to a complete remission. This report describes our successful experience using rituximab to treat refractory nephrotic syndrome of purpura nephritis. Further studies are required to confirm the efficacy of rituximab as an alternative therapy for nephrotic syndrome.
authors.affiliation: Department of Medical Science and Cardiorenal Medicine, Yokohama City University School of Medicine, Japan.
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Ishiguro
authors.forename: Tatsuo
authors.initials: T
authors.lastname: Hashimoto
authors.forename: Mariko
authors.initials: M
authors.lastname: Akata
authors.forename: Shota
authors.initials: S
authors.lastname: Suzuki
authors.forename: Kengo
authors.initials: K
authors.lastname: Azushima
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Kobayashi
authors.forename: Tomohiko
authors.initials: T
authors.lastname: Kanaoka
authors.forename: Shinichiro
authors.initials: S
authors.lastname: Yoshida
authors.forename: Hiromichi
authors.initials: H
authors.lastname: Wakui
authors.forename: Jin
authors.initials: J
authors.lastname: Oshikawa
authors.forename: Kiyotaka
authors.initials: K
authors.lastname: Nagahama
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Inayama
authors.forename: Kouichi
authors.initials: K
authors.lastname: Tamura
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Toya
authors.forename: Satoshi
authors.initials: S
authors.lastname: Umemura
mesh_terms: D000284:Administration, Oral; D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D000924:Anticholesteremic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy / Q000209:etiology; D011695:IgA Vasculitis / Q000150:complications / Q000188:drug therapy*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007262:Infusions, Intravenous; D008775:Methylprednisolone / Q000008:administration & dosage / Q000627:therapeutic use; D009393:Nephritis / Q000209:etiology* / Q000473:pathology; D009404:Nephrotic Syndrome / Q000209:etiology* / Q000473:pathology; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D011239:Prednisolone / Q000008:administration & dosage / Q000627:therapeutic use; D011507:Proteinuria / Q000209:etiology; D012074:Remission Induction; D000069283:Rituximab
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000924:Anticholesteremic Agents; D007166:Immunosuppressive Agents; D010975:Platelet Aggregation Inhibitors; D000069283:Rituximab; D003520:Cyclophosphamide; D011239:Prednisolone; D008775:Methylprednisolone